Abstract
The initial stages of the CoVID-19 coronavirus pandemic all around the world exhibit a nearly exponential rise in the number of infections with time. Planners, governments, and agencies are scrambling to figure out “How much? How bad?” and how to effectively treat the potentially large numbers of simultaneously sick people. Modeling the CoVID-19 pandemic using an exponential rise implicitly assumes a nearly unlimited population of uninfected persons (“dilute pandemic”). Once a significant fraction of the population is infected (“saturated pandemic”), an exponential growth no longer applies. A new model is developed here, which modifies the standard exponential growth function to account for factors such as Social Distancing. A Social Mitigation Parameter [SMP] αS is introduced to account for these types of society-wide changes, which can modify the standard exponential growth function, as follows:
The doubling-time tdbl = (In 2)/Ko can also be used to substitute for Ko, giving a {tdbl, αS} parameter pair for comparing to actual CoVID-19 data. This model shows how the number of CoVID-19 infections can self-limit before reaching a saturated pandemic level. It also provides estimates for: (a) the timing of the pandemic peak, (b) the maximum number of new daily cases that would be expected, and (c) the expected total number of CoVID-19 cases. This model shows fairly good agreement with the presently available CoVID-19 pandemic data for several individual States, and the for the USA as a whole (6 Figures), as well as for various countries around the World (9 Figures). An augmented model with two Mitigation Parameters, αS and βS, is also developed, which can give better agreement with the daily new CoVID-19 data. Data-to-model comparisons also indicate that using αS by itself likely provides a worst-case estimate, while using both αS and βS likely provides a best-case estimate for the CoVID-19 spread.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was used in creation of this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
CC BY: All data and analyses are publicly available
